Biallelic glucocerebrosidase (GBA) mutations cause the lysosomal storage disorder Gaucher disease (GD), while heterozygous GBA variants are the strongest and most common genetic risk factor for Parkinson disease (PD). An excessive burden of other lysosomal storage disorder gene variants, in particular for SMPD1 (encoding for acid sphingomyelinase (ASM)) has also been reported in PD. However, it is unclear whether GBA and SMPD1 interact genetically. Zebrafish are an ideal vertebrate system to test for such interactions. We previously characterised a gba1 -/mutant zebrafish line which displayed key hallmarks of human GD. In this work, we describe the biological interaction of combined glucocerebrosidase (GCase) and ASM deficiency in gba1 -/-;smpd1 -/double mutant zebrafish. We observed a marked increase of glucosylceramide, ceramide and other key sphingolipids or their metabolites in gba1 -
Introduction
Monogenically inherited forms of Parkinson's disease (PD) due to mutations in Mendelian PARK genes such as SNCA, LRRK2 or parkin can only be detected in 5-10% of PD patients in most populations (1) . Hypothesis-driven research combined with genome-wide association studies (GWAS) have identified > 30 putative or definitive PD risk genes but the effect of each individual risk gene is typically small (2) . A popular but largely unproven hypothesis is an additive effect of risk haplotypes, based on the assumption that the risk of PD correlates with the number of risk variants present in an individual.
Biallelic mutations in the glucocerebrosidase 1 (GBA1) gene lead to the lysosomal storage disorder Gaucher's disease (GD). Genetic inactivation of GBA1 results in decreased activity of the lysosomal enzyme glucocerebrosidase (GCase) which hydrolyses glucosylceramide to ceramide and glucose. The key pathological feature of GD is the accumulation of lipid laden macrophages called "Gaucher cells", resulting in splenomegaly, hepatomegaly and dysfunction of other organs including the brain (3, 4) . Three subtypes of GD with markedly different age at onset and disease severity are recognized but the factors influencing the specific disease phenotype in individual GD patients are largely unknown (5) . Heterozygous GBA1 mutations are the most common and strongest genetic risk factor for the common neurodegenerative disorder Parkinson's disease (PD) with a prevalence of ~ 5-20%, depending on the population investigated (6) (7) (8) . Heterozygote GBA1 mutation carriers have a 10%-30% risk of developing PD by age 80 up to a 20-fold increase compared to non-carriers (9, 10) .
Severe GBA1 mutations confer a considerably higher risk of PD than mild mutations (11) . However, no additional factors other than age or the severity of the GBA1 mutation have been identified which would explain the highly variable penetrance of PD in GBA1 mutations carriers. Of note, sequence variants in other lysosomal disease genes (LSD) were subsequently identified as additional and separate risk factors for 5 PD (12) . There is particularly strong evidence for an association with variants in the SMPD1 gene (encoding for acid sphingomyelinase (ASM)), the causative gene of Niemann-Pick disease A/B (13) .
Zebrafish (Danio rerio) are an ideally suited vertebrate model to study gene-gene interactions due to their short generation time, high fecundity and ease of housing.
Gene editing tools such as transcription activator-like effector nucleases (TALENs) or clustered regular interspersed short palindromic repeat (CRISPR) systems are widely used in zebrafish research (14) . We had previously characterised a gba1 mutant zebrafish line (gba1 -/-) (15) . gba1 -/zebrafish faithfully modelled key features of GD including Gaucher cell accumulation, marked microglial infiltration and neurodegeneration. gba1 -/larvae develop normally despite crucial consequences of GCase deficiency such as early microglial activation and GCase substrate accumulation already being present at 5 days post fertilization (dpf). From 10-12 weeks onwards, gba1 -/juvenile zebrafish rapidly deteriorate and die or must be culled for animal welfare reasons at 12-14 weeks.
As both GCase and ASM are lysosomal hydrolases linked to sporadic PD, we hypothesised that ASM deficiency could accelerate disease progression and enhance the phenotype in GCase deficient gba1 -/zebrafish. Unexpectedly, we observed a rescue effect of ASM deficiency with prolonged survival due to marked improvement of mitochondrial function and reduced oxidative stress in gba1 -/-;smpd1 -/zebrafish.
Complementary work in human neuroblastoma SH-SY5Y cells demonstrated that dual
ASM and GCase deficiency also results in a significant decrease in α-synuclein levels (when compared to cells with just GCase deficiency) which is not due to changes to macroautophagy flux.
Results

smpd1 -/zebrafish display abolished acid sphingomyelinase activity and marked sphingolipid accumulation
We identified a single smpd1 orthologue in zebrafish (ENSDARG00000076121) with 59% shared identity to the human SMPD1 gene at both the DNA and the protein level. CRISPR/Cas9 technology was used to generate a smpd1 stable mutant line (smpd1 -/-). The selected mutant allele contained a 5bp deletion and 136bp insertion within exon 3, resulting in a frame-shift and the generation of a premature stop codon ( Fig. 1A and SI Appendix Fig. S1 ). Enzymatic activity of ASM in smpd1 -/at 5 dpf was reduced by 93% (4.3 nmol/18 h/mg protein, n=6 vs. 64 nmol/18 h/mg protein, n= 7, p=0.006,
The large reduction in ASM enzymatic activity resulted in a significant increase of key glycolipid substrates in the smpd1 -/larvae already at 5 dpf (Fig. 1C ). This included sphingomyelin (102% increase, p=0.0002), di-hydrosphingomyelin (105% increase, p=0.004), ceramide (27% increase, p=0.0067), lactosylceramide (50% increase, p=0.0191), sphinganine (114% increase, p=0.0007) and sphinganine-1-phosphate (80% increase, p=0.0093).
Combined ASM and GCase deficiency synergistically increases sphingolipid metabolites
We had previously reported marked sphingolipid accumulation in gba1 -/zebrafish (15) .
We hypothesised that combined (enzymatic) GCase and ASM deficiency would synergistically increase distinct sphingolipid subtypes. Using mass spectrometry, a comprehensive panel of glycolipid substrates was analysed in the brains of gba -/and smpd1 -/-(single mutant) as well as in gba -/-;smpd1 -/-(double mutant) zebrafish and WT controls at 12 weeks of age.
Glucosylceramide levels (the direct substrate of GCase) were not significantly changed in smpd1 -/brains compared to WT, but were increased by 31517% above WT levels in gba1 -/brains (p<0.0001, Fig. 2A ) with a further marked synergistic increase in glucosylceramide levels by 16609% in the gba -/-;smpd1 -/double mutants with glucosylceramide levels reaching an increase of 48126% compared to WT (p<0.0001, Fig. 2A ).
Lactosylceramide levels demonstrated a similar trend across the four genotypes. smpd1 -/brains did not have a significant increase in lactosylceramide levels compared to WT, but gba1 -/showed a marked increase of 4028% compared to WT (p<0.0001, Fig. 2B ) and there was then a further synergistic increase in gba -/-;smpd1 -/double mutants to 4724% above WT levels (p<0.0001, Fig. 2B ). This 696% increase in lactosylceramide levels between gba -/and gba -/-;smpd1 -/again demonstrated synergy between the two different genotypes (p=0.0191).
Ceramide levels were raised by 106% in smpd1 -/and 88% in gba1 -/compared to WT (p<0.0001 for both, Fig. 2C ), with gba -/-;smpd1 -/showing an additive 200% ceramide increase compared to WT (p<0.0001 compared to gba1 -/-, smpd1 -/and WT, Fig. 2C ).
Sphinganine levels were raised by 95% in smpd1 -/-(p<0.0001 Fig. 2D ) and by 46% in gba1 -/-(p=0.0383, Fig. 2D ) and an increase by 225% in gba -/-;smpd1 -/compared to WT (p<0.0001 compared to gba1 -/-, smpd1 -/and WT).
Similarly but in a less pronounced manner, sphingosine levels were increased in smpd1 -/by 60% compared to WT (p<0.0001, Fig. 2E ) but only increased by 35% in gba1 -/-(p=0.0025, Fig. 2E ). Sphingosine levels were increased to 84% in gba -/-;smpd1 -/compared to WT (p<0.0001, Fig. 2E ), reflecting an significant increase compared to gba1 -/-(p<0.0001, Fig. 2E ) but not compared to smpd1 -/-(p>0.05, Fig. 2E ). In contrast, Sphingomyelin, the direct substrate of acid sphingomyelinase had a marked accumulation of 288% in smpd1 -/compared to WT levels (p<0.0001, Fig. 2F ), but was unchanged in gba1 -/-. Unexpectedly, there was no synergistic effect in sphingomyelin levels in the double mutants, which demonstrated a comparable increase to that seen in smpd1 -/compared to WT of 309% (p<0.0001, Fig. 2F ).
Chitotriosidase and β-Hexosaminidase are markedly increased in the serum of GD patients and used as biomarkers to monitor disease activity (3) . We previously observed a marked increase in chitotriosidase and β-hexosaminidase activity in gba1 -/zebrafish brain tissue at 12 weeks (15) . As key GCase substrates were synergistically increased in gba -/-;smpd1 -/double mutant zebrafish, we investigated whether combined GCase and ASM inactivation may also result in a further increase chitotriosidase and β-hexosaminidase activity (SI Appendix, Fig 2) . As expected, βhexosaminidase activity was similar in smpd1 -/and WT, but markedly elevated in gba1 -/by 85% (2284±200 nmol/hr/mg protein, p<0.0001, n= 5, SI Appendix, Fig. 2A ) compared to WT (1234±47.3nmol/hr/mg protein). Unexpectedly, double mutants displayed a similar increase in activity to gba1 -/by 70% (2131±272.2nmol/hr/mg protein, p<0.0001, n=5, SI Appendix, Fig. 2A ) compared to WT. Chitotriosidase activity was again similar in smpd1 -/compared to WT, but markedly increased in gba1 -/by 389% (31.8±11.95 nm/hr/mg protein, p=0.0002, n=5, SI Appendix, Fig. 2B ) compared to WT levels (6.5±4.0 nm/hr/mh protein n=5). Brains from gba -/-;smpd1 -/double mutant zebrafish showed a large 230% increase in chitotriosidase activity (21.5±5.1nm/hr/mg protein, p=0.0177, n=5 SI Appendix, Fig. 2B ) compared to WT.
Although this increase was not as large as that seen in gba1 -/-(230% increase compared to 389% increase), the differences in activities between gba1 -/and double mutants was not significant. β--galactosidase activity was used a control enzyme and as expected, all genotypes showed comparable activities of approximately 50nm/hr/mg protein, (n=5 for all genotypes, SI Appendix, Fig. 2C ).
Acid sphingomyelinase deficiency prolongs survival of gba -/due to rescue of mitochondrial function and reduction of oxidative stress
The marked synergistic effect of combined deficiency of GCase and acid sphingomyelinase activity on key sphingolipids in the gba -/-;smpd1 -/double mutant zebrafish suggested a possible effect of ASM activity on clinically relevant aspects of our gba1 -/zebrafish, in particular behaviour and survival. End stage gba1 -/mutants exhibit very robust behavioural phenotypes with barrel rolling like behaviour (15) .
Unexpectedly, genetic inactivation of ASM led to a complete rescue of this behaviour in the gba -/-;smpd1 -/double mutant zebrafish (SI Appendix, Video S1 (WT), S2 (smpd1 -/-), S3 (gba1 -/-) and S4 (gba -/-;smpd1 -/-)). We also observed a marked increase in lifespan by 23 days (22%) in gba1 -/-;smpd1 -/double mutant zebrafish compared to gba1 -/-(median survival of 102 dpf in gba1 -/and 125dpf in gba1 -/-;smpd1 -/-, p=0.0055,
Mitochondrial function is markedly impaired in GCase deficiency and other lysosomal storage disorders (16, 17) . We had previously observed a marked reduction of mitochondrial respiratory chain Complex IV activity and, to a lesser extent, also of Complex III in gba1 -/- (15) . We hypothesised that the observed partial rescue effect of acid sphingomyelinase deficiency on behaviour and survival of the gba -/zebrafish may be due to a rescue of the impaired mitochondrial respiratory chain function. As predicted, mitochondrial dysfunction in both gba -/and smpd1 -/zebrafish improved considerably in gba1 -/-;smpd1 -/-. Complex I activity was reduced by 65% in smpd1 -/-compared to WT levels (p=0.0198, Fig 3B) but restored to 92% of WT levels in gba1 -/-;smpd1 -/-(p=0.0445, Fig 3B) . Complex II was not significantly altered in any of the genotypes (Fig. 3C ). Complex III activity in gba1 -/was reduced by 45% compared to WT levels (p=0.0091, Fig. 3D ) as previously observed (15) . In contrast, Complex III activity in the gba1 -/-;smpd1 -/double mutant zebrafish was reduced by only 9% compared to WT levels and thus considerably less pronounced than the reduction observed in the gba1 -/-, suggesting a rescue effect in gba1 -/-;smpd1 -/-. However, this 36% increase in complex III activity in gba1 -/-;smpd1 -/compared to gba1 -/did not reach statistical significance. Complex IV activity was unchanged in smpd1 -/compared to WT, but reduced by 40% in gba1 -/compared to WT as previously reported (p=0.0491, Fig. 3E ). Remarkably, there was a marked improvement of complex IV activity in gba1 -
/-
;smpd1 -/with an increase in activity of 69% compared to gba1 -/-(p= 0.0005, Fig. 3E ).
Malfunction of the mitochondrial respiratory chain can result in oxidative stress and subsequent lipid peroxidation. We therefore investigated next whether the observed rescue in mitochondrial function results in reduced oxidative stress-related damage.
Lipid peroxidation was increased in gba1 -/brains by 63% above WT levels (p= 0.0214, Fig. 3F ). As predicted, lipid peroxidation levels were reduced by 70% in gba1 -/-;smpd1 -/double mutants compared to gba1 -/and thus effectively normalized (p=0.0094, Fig.   3F ).
Dual GCase and ASM inhibition leads to a decrease in α-synuclein levels
Given the effect of (isolated) GCase or ASM deficiency on α-synuclein in PD (13, 18) , we also wanted to investigate the effect of combined GCase and ASM deficiency on α-synuclein homeostasis. The zebrafish genome does not contain α-synuclein. We therefore investigated the combined effect of ASM and GCase deficiency on αsynuclein homeostasis in a previously established human dopaminergic SH-SY5Y neuroblastoma cell line (19) . A siRNA-approach was applied to inactivate SMPD1/ASM, GCase was inhibited with conduritol B-epoxide (CBE) for 10 days (19) .
SMPD1 mRNA levels in the absence or presence of CBE were significantly decreased relative to scrambled (scram) control treated cells (65±19% and 64±15% reduction, respectively; p =0.0003 and 0.0007, Fig 4A] . Treatment with CBE alone or in the presence of SMPD1 siRNA significantly decreased GCase activity [79% and 76% reduction, respectively; P< 0.01)] relative to scram treated cells (19) . Notably GCase activity was significantly increased in SMPD1 knock down cells, compared to scram (15% increase; P < 0.05, Fig 4B) . Unexpectedly, the levels of α-synuclein were significantly decreased (rather than increased as predicted) in SMPD1-KD + CBEtreated cells (42% reduction relative to scram treated cells; p=0.0139, Fig. 4C and D) , when compared to CBE-treated cells. The decrease in intracellular α-synuclein levels in SMPD1-KD+CBE was not due to increased release of α-synuclein in to the media ( Fig. 4E ) or becoming insoluble (data not shown). Inhibition of ASM is known to promote autophagy (20) . We (MG, AS) and others had previously observed impaired autophagy/mitophagy in GCase deficiency (19, 21, 22) . We therefore assessed next whether the observed reduction in α-synuclein levels may be due to enhanced autophagy in tissue which is both GCase and ASM deficient. We measured macroautophagy flux by measuring the levels of LC3-II by western blot, a marker for autophagosome number. Under basal conditions, LC3-II levels were similar in all groups. As expected treatment with bafilomycin A1, which prevents the fusion of lysosomes with autophagosomes, caused an accumulation of autophagosomes, and was similar in all groups (Fig. 4F-G) . These data suggest that there is neither an impairment nor increase in macroautophagy flux under any conditions. However, no significant changes in either total cellular cholesterol levels, or its localisation were detected in SMPD1-KD cells, relative to the other groups (SI Appendix, Fig. S3E+F ).
Discussion
Both GBA1 and SMPD1 variants are firmly established inherited risk factors for PD.
Additional lysosomal storage disease (LSD) genes such as CTSD, SLC17A5 and ASAH1 have also been implicated (12, 24) . Biochemically, GCase and acid sphingomyelinase both play a key role in sphingolipid metabolism (25) . We therefore hypothesized that ASM deficiency would further enhance the phenotype and accelerate disease progression in GCase-deficient zebrafish. However, unexpectedly, (20, 26, 27) . Partial ASM inhibition restored autophagic dysfunction in AD patient-derived neurons as well as ameliorating the autophagic defect in in AD mice, resulting in a reduction of amyloid-beta deposition and improved memory impairment (28) . However, in our human dopaminergic cell culture models, macroautophagy flux appeared unaffected in either ASM deficiency alone, or in cells with both decreased ASM and GCase. It should be noted that we had previously observed > 95% GCase inhibition after treatment with 10 uM CBE (19) , whereas GCase activity was reduced to ~ 80% only in the presence of the transfection reagent required for the knockdown of ASM in this study. This likely explains why the trend for increased α-synuclein levels in the CBE-only treatment arm was not statistically significant but is still comparable to previous results from CBE-mediated GCase inhibition in SH-SY5Y cells (19) and mouse brain (29) . The remarkable decrease in soluble monomeric α-synuclein in cells with combined ASM and GCase deficiency may reflect a link between tightly controlled sphingolipid metabolism and α-synuclein homeostasis. However, the zebrafish genome does not contain an orthologue of α-synuclein. Thus, the observed partial rescue effect of ASM deficiency in our GCase deficient zebrafish model cannot be due to modulation of α-synuclein levels in gba -/-;smpd1 -/-. Given both enzymes are involved in sphingolipid metabolism, it is probable that changes in the glycosphingolipid profile of the cell contribute to the changes observed. Previous reports have also demonstrated that modulation of the glycosphingolipid profile in GCase deficient cells, other than restoration of GCase activity, can improve α-synuclein homeostasis (30, 31) .
Although unexpected, we are not the first to report a rescue effect of double knockout of lysosomal hydrolases or their paralogues. GBA2 inactivation had a marked rescue effect on the phenotype typically observed in conditional GBA1 knockout mouse models, whilst simultaneous knock out of galactosylceramidase and beta galactosidase dramatically extended lifespan of galactosylceramidase knockout mice (32, 33) . Zebrafish are ideally suited to study gene-gene interactions in a vertebrate model system of human disease (34) (35) (36) (37) . Future studies are needed to determine the functional interaction of other PD risk genes, especially those acting in shared pathways such as LSD genes. 
Materials and Methods
Zebrafish
Mutant line generation and line maintenance.
The gba1 -/mutant lines was generated using TALEN technology (15) . The smpd1 -/mutant line was generated by the Crispr/Cas9 method as previously described (38) . The following ultramer template was used: 5'-AAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTA ACTTGCTATTTCTAGCTCTAAAACGGATTGAGGCTTGTGTCTCcCTATAGTGAGT CGTATTACGC). The smpd1 -/line was genotyped using primers F 5'-AGCCGTGGTGGTTTCTACAG and R 5'-CCTTCTCTCCCTTGTTCTCG. The smpd1 -/line was crossed to gba1 +/to generate double heterozygous individuals. These were subsequently in-crossed to generate double mutants. At each in-cross larvae were genotyped at 3dpf by larval tail biopsy as previously described (39) . Each genotyped was raised in genotype-specific tanks at a density of 10-15 fish per tank. All individuals were re-genotyped at 10 weeks post-fertilisation. smpd1 +/were crossed with gba1 +/to generate gba1 +/-;smpd1 +/-. These were subsequently in-crossed to generate double mutants, single mutants and WT controls.
Biochemical activity assays and mass spectrometry. Sphingomyelinase activity was determined using homogenates prepared as follows. Tubes containing twenty embryos (5 dpf) were sonicated in 500 μl MilliQ and centrifuged (11000 rpm). ASM activities were measured using 20 μL supernatant and incubated with substrate HMU-PC (6-hexadecanoylamino-4-methylumbelliferyl-phosphorylcholine 0.66 mM, 20 μL, Moscerdam Substrates, NL) at pH 5.2 and 37 °C during 2 hours. Fluorescence intensity was measured at 415 (ex) and 460 (em) nm using a plate reader (LS55, Perkin Elmer). Lysosomal and mitochondrial enzyme assays as well as mass spectrometry were undertaken as previously described (15) . . These data were normalised to WT levels, indicated by the dashed line at 1.0. Sphingomyelin was elevated by 102%±30% above WT levels (Sph, p=0.0002). Dihydro-sphingomyelin was elevated by 105%±31% above WT levels (DHSph, p=0.0004). Ceramide was elevated by 27%±15% above WT levels (Cer, p=0.0067). Lactosylceramide was elevated by 51%±26% above WT levels (LacCer, p=0.0191). Sphinganine was elevated by 100%±43% above WT levels (Spgn, p=0.0007). Sphinganine 1 phosphate was elevated by 83%±51% above WT levels (Sa1P, p=0.093). All metabolites shown are the C18 neuronal species. Data represented are the mean ±SD. Statistical analysis was performed using two-tailed t-test. ****p<0.0001, ***p<0.001, **p<0.01 and *p<0.05. 
Video legends:
All videos were taken when the respective zebrafish were 12 weeks of age.
V-S1: Normal swimming behaviour in WT. All adults placed into a novel tank swim to the bottom momentarily before resuming standard swimming, balance and buoyancy maintained.
V-S2:
Normal swimming behaviour in smpd -/-. All adults placed into a novel tank swim to the bottom momentarily before resuming standard swimming, balance and buoyancy maintained.
V-S3:
Markedly abnormal swimming behaviour in gba -/with typical "corkscrew" swimming pattern. All adults placed into a novel tank swim in circular motions with balance and buoyancy defects. These increase with frequency and duration at end stage until they need to be culled for humane reasons.
V-S4:
Normalised swimming behaviour in gba -/-;smpd -/-. All adults placed into a novel tank swim to the bottom momentarily before resuming standard swimming, balance and buoyancy maintained.
